Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(11%)
Results Posted
120%(6 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
6
67%
Ph phase_3
1
11%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Terminated2
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 26 (66.7%)
Phase 31 (11.1%)

Trials by Status

unknown111%
active_not_recruiting111%
terminated222%
completed556%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_2

Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

NCT05727384
completedphase_2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
terminatedphase_3

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910
completedphase_1

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
active_not_recruitingphase_1

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05727384Phase 2

Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

Completed
NCT04129931Phase 2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
NCT03744910Phase 3

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
NCT03380377Phase 1

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Completed
NCT03380962Phase 1

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Active Not Recruiting
NCT04348500Phase 2

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

Completed
NCT04381052Phase 2

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Terminated
NCT02015520Phase 2

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed
NCT04494724Phase 2

Clazakizumab vs. Placebo - COVID-19 Infection

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9